Drug Approval | April 20, 2022
BDR Pharmaceuticals launch Furmecil to treat advanced gastric cancer
The launch is yet another first of its kind innovation in India
The launch is yet another first of its kind innovation in India
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
The expansion positions Cambrex with the largest and most advanced API facility in the United States
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Under the terms of the agreement, Vipergen will apply its in-living-cell DNA-encoded library (DEL) screening platform to discover novel small-molecule compounds that bind to a selected Theseus kinase target
Subscribe To Our Newsletter & Stay Updated
